Invega Sustenna 234 mg is a long-acting injectable antipsychotic medication used to treat schizophrenia and schizoaffective disorder [1]. It is administered intramuscularly, meaning it is injected into a muscle, typically once every two weeks [1]. The 234 mg dose represents the highest available strength for Invega Sustenna [1].
How does Invega Sustenna work?
Invega Sustenna is the brand name for paliperidone palmitate, a long-acting injectable form of paliperidone [1]. Paliperidone is an atypical antipsychotic that works by affecting dopamine and serotonin receptors in the brain [2]. By influencing these neurotransmitters, it helps to manage symptoms of psychosis, such as hallucinations, delusions, and disorganized thinking [2]. The injectable formulation allows for a slow and steady release of the medication over a two-week period, which can improve adherence compared to daily oral medications [3].
When does the patent for Invega Sustenna expire?
The patent landscape for Invega Sustenna is complex and involves multiple patents covering the drug and its formulations [4]. Information on specific patent expiry dates for Invega Sustenna can be found on DrugPatentWatch.com [4]. Companies often seek to extend patent protection through various means, including new formulation patents or method-of-use patents [4].
Who makes Invega Sustenna?
Invega Sustenna is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1]. Janssen is responsible for the development, marketing, and distribution of the medication [1].
What are the side effects of Invega Sustenna?
Common side effects associated with Invega Sustenna include [1]:
* Weight gain
* Drowsiness or sedation
* Dizziness
* Headache
* Dry mouth
* Constipation
* Increased prolactin levels, which can lead to menstrual irregularities, sexual dysfunction, and breast enlargement in men [2][5].
More serious, though less common, side effects can include movement disorders like tardive dyskinesia, metabolic changes (e.g., increased blood sugar, cholesterol), and neuroleptic malignant syndrome [1][2].
Can generic versions of Invega Sustenna be made?
The availability of generic versions of long-acting injectable medications like Invega Sustenna is often delayed by patent protections [4]. While the primary patents on the active ingredient may expire, secondary patents related to the formulation, manufacturing process, or delivery system can extend market exclusivity [4]. The development of a generic equivalent for a long-acting injectable is also technically challenging, requiring the ability to replicate the specific drug release profile [3].
What are the alternatives to Invega Sustenna?
Alternatives to Invega Sustenna include other long-acting injectable antipsychotics, as well as daily oral antipsychotic medications [6]. Other long-acting injectables available may have different dosing intervals (e.g., monthly or every three months) and mechanisms of action [6]. The choice of alternative depends on individual patient needs, treatment history, and physician recommendation [6].
What is the difference between Invega Sustenna and Invega?
Invega Sustenna is the long-acting injectable formulation of paliperidone palmitate, designed for bi-weekly administration [1]. The original Invega is an oral tablet formulation of paliperidone, taken daily [1]. The sustained release mechanism of Invega Sustenna aims to provide consistent medication levels over time, potentially improving adherence and reducing symptom relapse compared to daily oral dosing [3].
Sources:
1. https://www.invegasustenna.com/
2. https://www.drugbank.ca/drugs/paliperidone
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197020/
4. https://drugpatentwatch.com/
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080893/
6. https://www.mayoclinic.org/diseases-conditions/schizophrenia/diagnosis-treatment/drc-20354451